Discover the story behind our beginnings and vision for the future.
Putnam has been a leader in life science consulting for over 30 years. We’re an Inizio Advisory company, known within our ecosystem for helping our clients build value and make confident decisions.
Today, our comprehensive suite of services across commercial, value, pricing, and access, and medical and scientific affairs are supporting our firm’s mission and our clients’ success.
What started as a small but mighty consulting group has grown into a leading scientific and strategic consulting partner with:
At Putnam, our global team of rigorously trained and highly engaged scientists and strategists dig deep to solve your most complex challenges and advance your innovations.
Who we are
We are a leading scientific and strategic consulting partner that helps the global life science community make confident decisions, build value, and bring life-changing innovations to clinicians and patients.
For more than 30 years, our rigorous, bespoke approach and globally diverse team have delivered unrivalled depth across therapeutic areas, business functions, geographic markets, healthcare sectors, and technology platforms to maximize the human impact and commercial success of client innovations.
Putnam bridges the highest levels of scientific and strategic excellence across the product development and commercialization lifecycle. We offer a breadth and depth of capabilities across areas.
We help you navigate complexities and develop bold strategies with centers of excellence in advanced clinical technologies, financial modeling and forecasting, and integrated insights.
Inizio Advisory is a trusted advisor for health and life science companies that leverages connected solutions and intelligence to turn science into strategy and execution for every stage of the journey from early commercialization to product launch and beyond.
Get the latest insights and perspectives from our experts.
Introduction The 2024 American Society of Hematology (ASH) Annual Meeting presented a wealth of data, unveiling the...
Discover insights into the evolving US vaccine landscape, trends, and strategic imperatives for successful novel vaccine launches. Download now!
Putnam shares key questions to consider in preparation of advancing trials and deals that have been put on hold.
Putnam predicts the 15 drugs likely to be selected for the second round of Medicare Price Negotiations.